Clinical pharmacogenetics implementation: Approaches, successes, and challenges. Issue 1 (10th March 2014)

• Record Type: Journal Article
• Authors: Weitzel, Kristin W.; Elsey, Amanda R.; Langaee, Taimour Y.; Burkley, Benjamin; Nessl, David R.; Obeng, Aniwaa Owusu; Staley, Benjamin J.; Dong, Hui‐Jia; Allan, Robert W.; Liu, J. Felix; Cooper‐DeHoff, Rhonda M.; Anderson, R. David; Conlon, Michael; Clare‐Salzler, Michael J.; Nelson, David R.; Johnson, Julie A.; Williams, Marc S.
• Is Part Of: American journal of medical genetics. Volume 166:Issue 1(2014)
• Page Start: 56
• Page End: 67
• Publication Date: 2014-03-10
• Subjects: Medical genetics -- Periodicals; 616.04205
• DOI: 10.1002/ajmg.c.31390
• Languages: English
• ISSNs: 1552-4868

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ajmgc31390-sec-0001" sec-type="section"> <p>Current challenges exist to widespread clinical implementation of genomic medicine and pharmacogenetics. The University of Florida (UF) Health Personalized Medicine Program (PMP) is a pharmacist‐led, multidisciplinary initiative created in 2011 within the UF Clinical Translational Science Institute. Initial efforts focused on pharmacogenetics, with long‐term goals to include expansion to disease‐risk prediction and disease stratification. Herein we describe the processes for development of the program, the challenges that were encountered and the clinical acceptance by clinicians of the genomic medicine implementation. The initial clinical implementation of the UF PMP began in June 2012 and targeted clopidogrel use and the <italic>CYP2C19</italic> genotype in patients undergoing left heart catheterization and percutaneous‐coronary intervention (PCI). After 1 year, 1, 097 patients undergoing left heart catheterization were genotyped preemptively, and 291 of those underwent subsequent PCI. Genotype results were reported to the medical record for 100% of genotyped patients. Eighty patients who underwent PCI had an actionable genotype, with drug therapy changes implemented in 56 individuals. Average turnaround time from blood draw to genotype result entry in the medical record was 3.5 business days. Seven different third party payors, including Medicare, reimbursed for the test during the first month of billing, with an 85% reimbursement rate for outpatient claims that were submitted in the first month. These data highlight multiple levels of success in clinical implementation of genomic medicine. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>